ESR1 and breast carcinoma: Very recently, Timilsina et al. demonstrated that imipramine triggers cell cycle arrest in triple-negative (TNBC) and estrogen-receptor-positive (ER+) breast cancers and by blocking heightened DNA double-strand breaks repair machinery.